Skip to main content
PMC home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1994 Oct;161(4):393–408.

Paradoxes of body fluid volume regulation in health and disease. A unifying hypothesis.

R W Schrier 1, M Niederberger 1
PMCID: PMC1022621  PMID: 7817551

Abstract

The body's normal homeostasis is maintained by the integrity of the excretory capacity of the kidneys. In advanced cardiac failure, however, the avidity of the renal sodium and water retention contributes to the occurrence of pulmonary congestion and peripheral edema. In patients with advanced cirrhosis, the kidneys again fail to excrete the amounts of sodium and water ingested, thus leading to ascites and peripheral edema. The signals for this renal retention of sodium and water in a patient with cirrhosis must be extrarenal because when the same kidneys are transplanted into persons with normal liver function, renal sodium and water retention no longer occurs; rather, the kidneys maintain normal fluid and electrolyte balance. Excessive sodium and water retention by the kidneys also occurs during pregnancy despite a 30% to 50% increase in plasma volume, cardiac output, and glomerular filtration rate. What are the afferent and efferent signals whereby normal kidneys retain sodium and water so that total extracellular, interstitial, and intravascular volumes expand far beyond those limits observed in normal subjects? These dilemmas are the subject of this review, in which a "unifying hypothesis of body fluid volume regulation" is presented.

Full text

PDF
407

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham W. T., Hensen J., Kim J. K., Dürr J., Lesnefsky E. J., Groves B. M., Schrier R. W. Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure. J Am Soc Nephrol. 1992 Jun;2(12):1697–1703. doi: 10.1681/ASN.V2121697. [DOI] [PubMed] [Google Scholar]
  2. Abraham W. T., Hensen J., Schrier R. W. Elevated plasma noradrenaline concentrations in patients with low-output cardiac failure: dependence on increased noradrenaline secretion rates. Clin Sci (Lond) 1990 Nov;79(5):429–435. doi: 10.1042/cs0790429. [DOI] [PubMed] [Google Scholar]
  3. Albillos A., Colombato L. A., Groszmann R. J. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology. 1992 Mar;102(3):931–935. doi: 10.1016/0016-5085(92)90179-3. [DOI] [PubMed] [Google Scholar]
  4. Anderson R. J., Chung H. M., Kluge R., Schrier R. W. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med. 1985 Feb;102(2):164–168. doi: 10.7326/0003-4819-102-2-164. [DOI] [PubMed] [Google Scholar]
  5. Baylis C., Reckelhoff J. F. Renal hemodynamics in normal and hypertensive pregnancy: lessons from micropuncture. Am J Kidney Dis. 1991 Feb;17(2):98–104. doi: 10.1016/s0272-6386(12)81111-5. [DOI] [PubMed] [Google Scholar]
  6. Bello-Reuss E. Effect of catecholamines on fluid reabsorption by the isolated proximal convoluted tubule. Am J Physiol. 1980 May;238(5):F347–F352. doi: 10.1152/ajprenal.1980.238.5.F347. [DOI] [PubMed] [Google Scholar]
  7. Bendtsen F., Schifter S., Henriksen J. H. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J Hepatol. 1991 Jan;12(1):118–123. doi: 10.1016/0168-8278(91)90920-7. [DOI] [PubMed] [Google Scholar]
  8. Benoit J. N., Zimmerman B., Premen A. J., Go V. L., Granger D. N. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol. 1986 Nov;251(5 Pt 1):G674–G677. doi: 10.1152/ajpgi.1986.251.5.G674. [DOI] [PubMed] [Google Scholar]
  9. Bichet D. G., Kortas C., Mettauer B., Manzini C., Marc-Aurèle J., Rouleau J. L., Schrier R. W. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int. 1986 Jun;29(6):1188–1196. doi: 10.1038/ki.1986.126. [DOI] [PubMed] [Google Scholar]
  10. Bichet D. G., Van Putten V. J., Schrier R. W. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med. 1982 Dec 16;307(25):1552–1557. doi: 10.1056/NEJM198212163072504. [DOI] [PubMed] [Google Scholar]
  11. Bruix J., Bosch J., Kravetz D., Mastai R., Rodés J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology. 1985 Feb;88(2):430–435. doi: 10.1016/0016-5085(85)90503-7. [DOI] [PubMed] [Google Scholar]
  12. Caramelo C., Fernández-Gallardo S., Santos J. C., Iñarrea P., Sánchez-Crespo M., López-Novoa J. M., Hernando L. Increased levels of platelet-activating factor in blood from patients with cirrhosis of the liver. Eur J Clin Invest. 1987 Feb;17(1):7–11. doi: 10.1111/j.1365-2362.1987.tb01218.x. [DOI] [PubMed] [Google Scholar]
  13. Claria J., Jiménez W., Arroyo V., Guarner F., López C., La Villa G., Asbert M., Rivera F., Rodés J. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology. 1989 Nov;97(5):1294–1299. doi: 10.1016/0016-5085(89)91702-2. [DOI] [PubMed] [Google Scholar]
  14. Claria J., Jiménez W., Arroyo V., La Villa G., López C., Asbert M., Castro A., Gaya J., Rivera F., Rodés J. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology. 1991 Feb;100(2):494–501. doi: 10.1016/0016-5085(91)90222-7. [DOI] [PubMed] [Google Scholar]
  15. Clària J., Jiménez W., Ros J., Asbert M., Castro A., Arroyo V., Rivera F., Rodés J. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology. 1992 Feb;15(2):343–349. doi: 10.1002/hep.1840150227. [DOI] [PubMed] [Google Scholar]
  16. Cody R. J., Atlas S. A., Laragh J. H., Kubo S. H., Covit A. B., Ryman K. S., Shaknovich A., Pondolfino K., Clark M., Camargo M. J. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986 Nov;78(5):1362–1374. doi: 10.1172/JCI112723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Conrad K. P., Joffe G. M., Kruszyna H., Kruszyna R., Rochelle L. G., Smith R. P., Chavez J. E., Mosher M. D. Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J. 1993 Apr 1;7(6):566–571. [PubMed] [Google Scholar]
  18. Conrad K. P., Morganelli P. M., Brinck-Johnsen T., Colpoys M. C. The renin-angiotensin system during pregnancy in chronically instrumented, conscious rats. Am J Obstet Gynecol. 1989 Oct;161(4):1065–1072. doi: 10.1016/0002-9378(89)90785-0. [DOI] [PubMed] [Google Scholar]
  19. Conrad K. P., Vernier K. A. Plasma level, urinary excretion, and metabolic production of cGMP during gestation in rats. Am J Physiol. 1989 Oct;257(4 Pt 2):R847–R853. doi: 10.1152/ajpregu.1989.257.4.R847. [DOI] [PubMed] [Google Scholar]
  20. Cosby R. L., Yee B., Schrier R. W. New classification with prognostic value in cirrhotic patients. Miner Electrolyte Metab. 1989;15(5):261–266. [PubMed] [Google Scholar]
  21. Davison J. M. Kidney function in pregnant women. Am J Kidney Dis. 1987 Apr;9(4):248–252. doi: 10.1016/s0272-6386(87)80117-8. [DOI] [PubMed] [Google Scholar]
  22. Durr J. A., Stamoutsos B., Lindheimer M. D. Osmoregulation during pregnancy in the rat. Evidence for resetting of the threshold for vasopressin secretion during gestation. J Clin Invest. 1981 Aug;68(2):337–346. doi: 10.1172/JCI110261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Dzau V. J., Colucci W. S., Hollenberg N. K., Williams G. H. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981 Mar;63(3):645–651. doi: 10.1161/01.cir.63.3.645. [DOI] [PubMed] [Google Scholar]
  24. Gaeta G. B., Perna P., Adinolfi L. E., Utili R., Ruggiero G. Endotoxemia in a series of 104 patients with chronic liver diseases: prevalence and significance. Digestion. 1982;23(4):239–244. doi: 10.1159/000198756. [DOI] [PubMed] [Google Scholar]
  25. Goy J. J., Waeber B., Nussberger J., Bidiville J., Biollaz J., Nicod P., Mooser V., Kappenberger L., Brunner H. R. Infusion of atrial natriuretic peptide to patients with congestive heart failure. J Cardiovasc Pharmacol. 1988;12(5):562–570. doi: 10.1097/00005344-198811000-00010. [DOI] [PubMed] [Google Scholar]
  26. Gray G. A., Schott C., Julou-Schaeffer G., Fleming I., Parratt J. R., Stoclet J. C. The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. Br J Pharmacol. 1991 May;103(1):1218–1224. doi: 10.1111/j.1476-5381.1991.tb12327.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Gregory P. B., Broekelschen P. H., Hill M. D., Lipton A. B., Knauer C. M., Egger M., Miller R. Complications of diuresis in the alcoholic patient with ascites: a controlled trial. Gastroenterology. 1977 Sep;73(3):534–538. [PubMed] [Google Scholar]
  28. Hayashi T., Fukuto J. M., Ignarro L. J., Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11259–11263. doi: 10.1073/pnas.89.23.11259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Henriksen J. H., Staun-Olsen P., Borg Mogensen N., Fahrenkrug J. Circulating endogenous vasoactive intestinal polypeptide (VIP) in patients with uraemia and liver cirrhosis. Eur J Clin Invest. 1986 Jun;16(3):211–216. doi: 10.1111/j.1365-2362.1986.tb01331.x. [DOI] [PubMed] [Google Scholar]
  30. Hensen J., Abraham W. T., Dürr J. A., Schrier R. W. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol. 1991;11(6):441–446. doi: 10.1159/000168356. [DOI] [PubMed] [Google Scholar]
  31. Hörtnagl H., Singer E. A., Lenz K., Kleinberger G., Lochs H. Substance P is markedly increased in plasma of patients with hepatic coma. Lancet. 1984 Mar 3;1(8375):480–483. doi: 10.1016/s0140-6736(84)92851-4. [DOI] [PubMed] [Google Scholar]
  32. Ishikawa S., Saito T., Okada K., Tsutsui K., Kuzuya T. Effect of vasopressin antagonist on water excretion in inferior vena cava constriction. Kidney Int. 1986 Jul;30(1):49–55. doi: 10.1038/ki.1986.149. [DOI] [PubMed] [Google Scholar]
  33. Iwatsuki S., Popovtzer M. M., Corman J. L., Ishikawa M., Putnam C. W., Katz F. H., Starzl T. E. Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. N Engl J Med. 1973 Nov 29;289(22):1155–1159. doi: 10.1056/NEJM197311292892201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Jespersen B., Jensen L., Sørensen S. S., Pedersen E. B. Atrial natriuretic factor, cyclic 3',5'-guanosine monophosphate and prostaglandin E2 in liver cirrhosis: relation to blood volume and changes in blood volume after furosemide. Eur J Clin Invest. 1990 Dec;20(6):632–641. doi: 10.1111/j.1365-2362.1990.tb01912.x. [DOI] [PubMed] [Google Scholar]
  35. Kim J. K., Michel J. B., Soubrier F., Durr J., Corvol P., Schrier R. W. Arginine vasopressin gene expression in chronic cardiac failure in rats. Kidney Int. 1990 Nov;38(5):818–822. doi: 10.1038/ki.1990.276. [DOI] [PubMed] [Google Scholar]
  36. Kim J. K., Summer S. N., Howard R. L., Schrier R. W. Vasopressin gene expression in rats with experimental cirrhosis. Hepatology. 1993 Jan;17(1):143–147. [PubMed] [Google Scholar]
  37. Koepke J. P., DiBona G. F. Blunted natriuresis to atrial natriuretic peptide in chronic sodium-retaining disorders. Am J Physiol. 1987 May;252(5 Pt 2):F865–F871. doi: 10.1152/ajprenal.1987.252.5.F865. [DOI] [PubMed] [Google Scholar]
  38. Koepke J. P., Jones S., DiBona G. F. Renal nerves mediate blunted natriuresis to atrial natriuretic peptide in cirrhotic rats. Am J Physiol. 1987 May;252(5 Pt 2):R1019–R1023. doi: 10.1152/ajpregu.1987.252.5.R1019. [DOI] [PubMed] [Google Scholar]
  39. Koppel M. H., Coburn J. W., Mims M. M., Goldstein H., Boyle J. D., Rubini M. E. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med. 1969 Jun 19;280(25):1367–1371. doi: 10.1056/NEJM196906192802501. [DOI] [PubMed] [Google Scholar]
  40. Kravetz D., Arderiu M., Bosch J., Fuster J., Visa J., Casamitjana R., Rodés J. Hyperglucagonemia and hyperkinetic circulation after portocaval shunt in the rat. Am J Physiol. 1987 Feb;252(2 Pt 1):G257–G261. doi: 10.1152/ajpgi.1987.252.2.G257. [DOI] [PubMed] [Google Scholar]
  41. La Villa G., Salmerón J. M., Arroyo V., Bosch J., Ginés P., García-Pagán J. C., Ginés A., Asbert M., Jiménez W., Rivera F. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology. 1992 Jun;102(6):2114–2119. doi: 10.1016/0016-5085(92)90340-5. [DOI] [PubMed] [Google Scholar]
  42. Laffi G., Pinzani M., Meacci E., La Villa G., Renzi D., Baldi E., Cominelli F., Marra F., Gentilini P. Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. Gastroenterology. 1989 Jan;96(1):167–177. doi: 10.1016/0016-5085(89)90777-4. [DOI] [PubMed] [Google Scholar]
  43. Lee M. E., Miller W. L., Edwards B. S., Burnett J. C., Jr Role of endogenous atrial natriuretic factor in acute congestive heart failure. J Clin Invest. 1989 Dec;84(6):1962–1966. doi: 10.1172/JCI114385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Lee W. H., Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986 Feb;73(2):257–267. doi: 10.1161/01.cir.73.2.257. [DOI] [PubMed] [Google Scholar]
  45. Levine T. B., Francis G. S., Goldsmith S. R., Simon A. B., Cohn J. N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982 May;49(7):1659–1666. doi: 10.1016/0002-9149(82)90243-0. [DOI] [PubMed] [Google Scholar]
  46. Liu F. Y., Cogan M. G. Angiotensin II: a potent regulator of acidification in the rat early proximal convoluted tubule. J Clin Invest. 1987 Jul;80(1):272–275. doi: 10.1172/JCI113059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Llach J., Ginès P., Arroyo V., Rimola A., Titó L., Badalamenti S., Jiménez W., Gaya J., Rivera F., Rodés J. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988 Feb;94(2):482–487. doi: 10.1016/0016-5085(88)90441-6. [DOI] [PubMed] [Google Scholar]
  48. Molnár M., Hertelendy F. N omega-nitro-L-arginine, an inhibitor of nitric oxide synthesis, increases blood pressure in rats and reverses the pregnancy-induced refractoriness to vasopressor agents. Am J Obstet Gynecol. 1992 May;166(5):1560–1567. doi: 10.1016/0002-9378(92)91634-m. [DOI] [PubMed] [Google Scholar]
  49. O'Connor K. J., Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase and the related cell damage in adenocarcinoma cells. Biochim Biophys Acta. 1991 Oct 21;1097(3):227–231. doi: 10.1016/0925-4439(91)90040-g. [DOI] [PubMed] [Google Scholar]
  50. PAPPER S. The role of the kidney in Laennec's cirrhosis of the liver. Medicine (Baltimore) 1958 Dec;37(4):299–316. doi: 10.1097/00005792-195812000-00002. [DOI] [PubMed] [Google Scholar]
  51. Petrillo A., Scherrer U., Gonvers J. J., Nussberger J., Marder H., de Vane P., Waeber B., Hofstetter J. R., Brunner H. R. Atrial natriuretic peptide administered as intravenous infusion or bolus injection to patients with liver cirrhosis and ascites. J Cardiovasc Pharmacol. 1988 Sep;12(3):279–285. doi: 10.1097/00005344-198809000-00004. [DOI] [PubMed] [Google Scholar]
  52. Riegger G. A., Elsner D., Kromer E. P., Daffner C., Forssmann W. G., Muders F., Pascher E. W., Kochsiek K. Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. Circulation. 1988 Feb;77(2):398–406. doi: 10.1161/01.cir.77.2.398. [DOI] [PubMed] [Google Scholar]
  53. Riegger G. A., Liebau G., Bauer E., Kochsiek K. Vasopressin and renin in high output heart failure of rats: hemodynamic effects of elevated plasma hormone levels. J Cardiovasc Pharmacol. 1985 Jan-Feb;7(1):1–5. doi: 10.1097/00005344-198501000-00001. [DOI] [PubMed] [Google Scholar]
  54. Robertson G. L. Thirst and vasopressin function in normal and disordered states of water balance. J Lab Clin Med. 1983 Mar;101(3):351–371. [PubMed] [Google Scholar]
  55. Sanz E., Caramelo C., López-Novoa J. M. Interstitial dynamics in rats with early stage experimental cirrhosis of the liver. Am J Physiol. 1989 Mar;256(3 Pt 2):F497–F503. doi: 10.1152/ajprenal.1989.256.3.F497. [DOI] [PubMed] [Google Scholar]
  56. Sanz E., López Novoa J. M., Linares M., Digiuni E., Caramelo C. A. Intravascular and interstitial fluid dynamics in rats treated with minoxidil. J Cardiovasc Pharmacol. 1990 Mar;15(3):485–492. doi: 10.1097/00005344-199003000-00020. [DOI] [PubMed] [Google Scholar]
  57. Sarrel P. M., Lindsay D. C., Poole-Wilson P. A., Collins P. Hypothesis: inhibition of endothelium-derived relaxing factor by haemoglobin in the pathogenesis of pre-eclampsia. Lancet. 1990 Oct 27;336(8722):1030–1032. doi: 10.1016/0140-6736(90)92490-9. [DOI] [PubMed] [Google Scholar]
  58. Schrier R. W. A unifying hypothesis of body fluid volume regulation. The Lilly Lecture 1992. J R Coll Physicians Lond. 1992 Jul;26(3):295–306. [PMC free article] [PubMed] [Google Scholar]
  59. Schrier R. W. An odyssey into the milieu intérieur: pondering the enigmas. J Am Soc Nephrol. 1992 May;2(11):1549–1559. doi: 10.1681/ASN.V2111549. [DOI] [PubMed] [Google Scholar]
  60. Schrier R. W., Arroyo V., Bernardi M., Epstein M., Henriksen J. H., Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988 Sep-Oct;8(5):1151–1157. doi: 10.1002/hep.1840080532. [DOI] [PubMed] [Google Scholar]
  61. Schrier R. W. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med. 1990 Jul 15;113(2):155–159. doi: 10.7326/0003-4819-113-2-155. [DOI] [PubMed] [Google Scholar]
  62. Schrier R. W., Briner V. A. Peripheral arterial vasodilation hypothesis of sodium and water retention in pregnancy: implications for pathogenesis of preeclampsia-eclampsia. Obstet Gynecol. 1991 Apr;77(4):632–639. [PubMed] [Google Scholar]
  63. Schrier R. W. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1) N Engl J Med. 1988 Oct 20;319(16):1065–1072. doi: 10.1056/NEJM198810203191606. [DOI] [PubMed] [Google Scholar]
  64. Schrier R. W. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2) N Engl J Med. 1988 Oct 27;319(17):1127–1134. doi: 10.1056/NEJM198810273191705. [DOI] [PubMed] [Google Scholar]
  65. Schuster V. L., Kokko J. P., Jacobson H. R. Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules. J Clin Invest. 1984 Feb;73(2):507–515. doi: 10.1172/JCI111237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Shapiro M. D., Nicholls K. M., Groves B. M., Kluge R., Chung H. M., Bichet D. G., Schrier R. W. Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients. Kidney Int. 1985 Aug;28(2):206–211. doi: 10.1038/ki.1985.142. [DOI] [PubMed] [Google Scholar]
  67. Shenker Y., Sider R. S., Ostafin E. A., Grekin R. J. Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J Clin Invest. 1985 Oct;76(4):1684–1687. doi: 10.1172/JCI112154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Silva G., Navasa M., Bosch J., Chesta J., Pilar Pizcueta M., Casamitjana R., Rivera F., Rodés J. Hemodynamic effects of glucagon in portal hypertension. Hepatology. 1990 Apr;11(4):668–673. doi: 10.1002/hep.1840110421. [DOI] [PubMed] [Google Scholar]
  69. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990 Nov;82(5):1730–1736. doi: 10.1161/01.cir.82.5.1730. [DOI] [PubMed] [Google Scholar]
  70. Szatalowicz V. L., Arnold P. E., Chaimovitz C., Bichet D., Berl T., Schrier R. W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981 Jul 30;305(5):263–266. doi: 10.1056/NEJM198107303050506. [DOI] [PubMed] [Google Scholar]
  71. Villamediana L. M., Sanz E., Fernandez-Gallardo S., Caramelo C., Sanchez Crespo M., Braquet P., Lopez-Novoa J. M. Effects of the platelet-activating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the liver. Life Sci. 1986 Jul 21;39(3):201–205. doi: 10.1016/0024-3205(86)90531-x. [DOI] [PubMed] [Google Scholar]
  72. Warren J. B., Coughlan M. L., Williams T. J. Endotoxin-induced vasodilatation in anaesthetized rat skin involves nitric oxide and prostaglandin synthesis. Br J Pharmacol. 1992 Aug;106(4):953–957. doi: 10.1111/j.1476-5381.1992.tb14441.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Yamamura Y., Ogawa H., Chihara T., Kondo K., Onogawa T., Nakamura S., Mori T., Tominaga M., Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991 Apr 26;252(5005):572–574. doi: 10.1126/science.1850553. [DOI] [PubMed] [Google Scholar]
  74. Yamamura Y., Ogawa H., Yamashita H., Chihara T., Miyamoto H., Nakamura S., Onogawa T., Yamashita T., Hosokawa T., Mori T. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992 Apr;105(4):787–791. doi: 10.1111/j.1476-5381.1992.tb09058.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. de Bold A. J., Borenstein H. B., Veress A. T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981 Jan 5;28(1):89–94. doi: 10.1016/0024-3205(81)90370-2. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES